The ANXA9 Knockout A-549 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout population designed to disrupt the ANXA9 gene in the human A-549 lung adenocarcinoma cell line. This product consists of a heterogeneous mixture of A-549 cells harboring targeted gene disruptions introduced by CRISPR/Cas9, offering a loss-of-function model that avoids clonal selection bias. The polyclonal format enables investigation of ANXA9 function within a population that retains biological variability, reflecting the complexity of tumor cell heterogeneity.
The host A-549 cell line is a hypotriploid epithelial line established from a lung adenocarcinoma of a 58-year-old Caucasian male. It is widely recognized as an in vitro model of alveolar type II epithelial cells and is routinely used in studies of lung adenocarcinoma biology and drug metabolism. The cells maintain epithelial characteristics and respond to key growth factors relevant to cancer signaling, making them a versatile platform for pathway analysis and therapeutic testing.
The ANXA9 protein is a calcium-dependent phospholipid-binding member of the annexin family that regulates membrane dynamics and participates in intracellular signaling networks. ANXA9 interacts with S100A10, S100A11, actin, and phospholipids, and its expression is modulated by upstream factors including EGF, TGF-??1, SP1, and NF-??B. Downstream, ANXA9 influences the expression or activity of PCNA, Cyclin D1, Bcl-2, and E-cadherin, thereby linking membrane events to cell proliferation and apoptosis. Pathway analysis suggests that ANXA9 knockout perturbs MAPK/ERK signaling (via ERK1/2), PI3K/AKT signaling (via AKT), and Wnt/??-catenin cascades, with additional involvement of JNK and p38 stress kinases.
In the context of A-549 lung adenocarcinoma cells, disruption of ANXA9 is expected to alter calcium-dependent membrane organization and suppress oncogenic signaling outputs. This may result in reduced proliferation, enhanced apoptosis, and impaired migration, driven by attenuated ERK1/2 and AKT phosphorylation and altered ??-catenin activity. The polyclonal knockout population provides a unique tool to study these effects in a heterogeneous background that mimics the clonal diversity observed in tumors.
Researchers can employ this product in a wide range of assays, including western blotting and RT-qPCR to assess gene and protein expression, MTT and Annexin V staining to measure viability and apoptosis, and wound healing or transwell migration assays to evaluate motility. Phospho-specific analysis of ERK1/2 and AKT can directly probe signaling alterations, while RNA-seq enables transcriptome-wide profiling. This model is well-suited for applications in lung adenocarcinoma research, drug resistance studies, annexin functional annotation, and cancer signaling dissection. For additional technical support, please contact Ascent Research.
